Minocycline is a semi-synthetic tetracycline antibiotic with antibacterial activity against both Gram-positive and Gram-negative bacteria. Its antibacterial spectrum is basically the same as that of tetracyclines, and it exerts its antimicrobial effect by inhibiting protein synthesis. This product is relatively sensitive to sensitive Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus, and Neisseria meningitidis, etc.) and Gram-negative bacteria (such as Neisseria gonorrhoeae, Haemophilus influenzae, etc.); it has a weaker effect on Gram-negative bacilli; and it has a certain effect on microorganisms such as Chlamydia trachomatis and Ureaplasma.

Minocycline is a semi-synthetic tetracycline antibiotic with antibacterial activity against both Gram-positive and Gram-negative bacteria. Its mechanism of action is to exert antimicrobial effects by inhibiting protein synthesis. This product is more sensitive to sensitive Gram-positive bacteria (including Staphylococcus aureus, Streptococcus, meningococcus, etc.) and Gram-negative bacteria (such as gonococci, Haemophilus influenzae, etc.); it has a weaker effect on Gram-negative bacilli; and has a certain effect on microorganisms such as Chlamydia trachomatis and Ureaplasma.

Minocycline is a semi-synthetic tetracycline antibiotic with antibacterial activity against both Gram-positive and Gram-negative bacteria. Its antibacterial spectrum is basically the same as that of tetracyclines. It exerts its antimicrobial effect by inhibiting protein synthesis. It is sensitive to sensitive Gram-positive bacteria, including Staphylococcus aureus, Streptococcus, and Neisseria meningitidis; it is relatively sensitive to Gram-negative bacteria, including Neisseria gonorrhoeae and Haemophilus influenzae; it has a weaker effect on Gram-negative bacilli; and it also has a certain effect on microorganisms such as Chlamydia trachomatis and Ureaplasma.

Minocycline is a semi-synthetic tetracycline antibiotic with antibacterial activity against both Gram-positive and Gram-negative bacteria. Its mechanism of action is to exert antimicrobial effects by inhibiting protein synthesis. This product is sensitive to sensitive Gram-positive bacteria, including Staphylococcus aureus, Streptococcus, and Neisseria meningitidis; it is relatively sensitive to Gram-negative bacteria, including Neisseria gonorrhoeae and Haemophilus influenzae; it has a weaker effect on Gram-negative bacilli; and it also has a certain effect on microorganisms such as Chlamydia trachomatis and Ureaplasma.

This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. It can not only non-competitively inhibit the gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basic gastric acid secretion that is not affected by choline or H2 receptor blockers. This product is metabolized through the first system of the cytochrome P450 enzyme system in liver cells, and can also be metabolized through the second system, reducing the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.